

Paola Rocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5465457/publications.pdf>

Version: 2024-02-01

96
papers

3,096
citations

147726

31
h-index

182361

51
g-index

98
all docs

98
docs citations

98
times ranked

3612
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	1.3	4
2	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 193-203.	1.1	4
3	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 161-170.	1.1	5
4	The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 772.	1.4	19
5	The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 18.	2.0	0
6	Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. <i>Microbial Biotechnology</i> , 2021, 15, 1136-1145.	0.9	23
7	Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 620.	1.8	5
8	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 11.	2.0	18
9	Updating and characterizing neuroanatomical markers in high-risk subjects, recently diagnosed and chronic patients with schizophrenia: A revised coordinate-based meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 123, 83-103.	2.9	40
10	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	6.0	89
11	The Management of Prodromal Symptoms of Bipolar Disorder: Available Options and Future Perspectives. <i>Medicina (Lithuania)</i> , 2021, 57, 545.	0.8	0
12	Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids. <i>Biomedicines</i> , 2021, 9, 850.	1.4	11
13	Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 649737.	1.3	7
14	Pharmacological Treatment for Social Cognition: Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7457.	1.8	3
15	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "œreal-life" Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110250.	2.5	18
16	The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 721361.	1.3	21
17	Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward. <i>Psychiatry Research</i> , 2021, 305, 114214.	1.7	1
18	How Interpersonal Psychotherapy Changes the Brain. <i>Journal of Clinical Psychiatry</i> , 2021, 83, .	1.1	5

#	ARTICLE	IF	CITATIONS
19	Borderline Personality Disorder: Risk Factors and Early Detection. <i>Diagnostics</i> , 2021, 11, 2142.	1.3	23
20	Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. <i>Diagnostics</i> , 2021, 11, 2146.	1.3	8
21	Questionnaire on Attitude towards Research and Care (QuARC): a survey of patients with psychosis. <i>Journal of Mental Health</i> , 2020, 29, 590-596.	1.0	0
22	Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 47-61.	0.9	24
23	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	4.8	96
24	Factors associated with 30-days and 180-days psychiatric readmissions: A snapshot of a metropolitan area. <i>Psychiatry Research</i> , 2020, 292, 113309.	1.7	8
25	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. <i>European Psychiatry</i> , 2020, 63, 1-21.	0.1	30
26	Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. <i>Clinical Drug Investigation</i> , 2020, 40, 861-871.	1.1	2
27	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. <i>European Psychiatry</i> , 2020, 63, e98.	0.1	20
28	Trauma and psychopathology associated with early onset BPD: an empirical contribution. <i>Journal of Psychiatric Research</i> , 2020, 131, 54-59.	1.5	11
29	Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6042.	1.8	12
30	Editorial: Psychosis and Personality Disorders: Do We Need Early Diagnosis for Successful Treatment?. <i>Frontiers in Psychiatry</i> , 2020, 11, 584.	1.3	0
31	Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 223.	1.3	15
32	Effectiveness of psychosocial treatments on symptoms and functional domains in schizophrenia spectrum disorders: a prospective study in a real-world setting. <i>Disability and Rehabilitation</i> , 2019, 41, 2799-2806.	0.9	5
33	Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5257.	1.8	33
34	Early Detection and Outcome in Borderline Personality Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 710.	1.3	37
35	Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 67.	1.3	60
36	Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study. <i>Heliyon</i> , 2019, 5, e01323.	1.4	19

#	ARTICLE	IF	CITATIONS
37	I do not know whether you did that: Abnormal implicit attribution of social causality in patients with schizophrenia. <i>Schizophrenia Research</i> , 2019, 210, 291-293.	1.1	3
38	Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. <i>Clinical Drug Investigation</i> , 2019, 39, 169-178.	1.1	11
39	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1033-1041.	2.3	88
40	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 126-136.	1.3	12
41	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	2.3	99
42	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	6.0	214
43	Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. <i>Clinical Drug Investigation</i> , 2018, 38, 367-372.	1.1	18
44	The complex relationship between self-reported "personal recovery"™ and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 108-112.	1.1	45
45	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , 2017, 247, 257-264.	1.7	32
46	Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. <i>CNS Drugs</i> , 2017, 31, 809-819.	2.7	19
47	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017, 256, 359-364.	1.7	49
48	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 285-294.	1.8	33
49	Pharmacotherapy of personality disorders: what we know and what we have to search for. <i>Future Neurology</i> , 2017, 12, 199-222.	0.9	4
50	Abnormal Sense of Agency in Patients with Schizophrenia: Evidence from Bimanual Coupling Paradigm. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 43.	1.0	46
51	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 917.	1.0	25
52	Coping strategies in schizoaffective disorder and schizophrenia: Differences and similarities. <i>Psychiatry Research</i> , 2016, 244, 317-323.	1.7	5
53	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2016, 175, 154-160.	1.1	66
54	Gender differences in 353 inpatients with acute psychosis: The experience of one Psychiatric Emergency Service of Turin. <i>Psychiatry Research</i> , 2015, 227, 192-197.	1.7	5

#	ARTICLE	IF	CITATIONS
55	Electroencephalographic connectivity analysis in schizophrenia. <i>Neuroscience Letters</i> , 2015, 604, 145-150.	1.0	7
56	Negative symptoms and everyday functioning in schizophrenia: A cross-sectional study in a real world-setting. <i>Psychiatry Research</i> , 2014, 218, 284-289.	1.7	82
57	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	4.8	346
58	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. <i>Schizophrenia Research</i> , 2014, 159, 144-150.	1.1	64
59	Relative contributions of negative symptoms, insight, and coping strategies to quality of life in stable schizophrenia. <i>Psychiatry Research</i> , 2014, 220, 102-111.	1.7	30
60	Quality of life in stable schizophrenia: The relative contributions of disorganization and cognitive dysfunction. <i>Schizophrenia Research</i> , 2014, 153, 196-203.	1.1	23
61	Substance use disorders in hospitalized psychiatric patients: The experience of one psychiatric emergency service in Turin. <i>Comprehensive Psychiatry</i> , 2014, 55, 1234-1243.	1.5	3
62	Cognitive functioning and insight in schizophrenia and in schizoaffective disorder. <i>Rivista Di Psichiatria</i> , 2014, 49, 77-83.	0.6	5
63	Clinical outcome and length of stay in an Italian Psychiatric Emergency Service. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1013-1020.	1.6	13
64	Insight in stable schizophrenia: Relations with psychopathology and cognition. <i>Comprehensive Psychiatry</i> , 2013, 54, 484-492.	1.5	26
65	Prosody recognition and audiovisual emotion matching in schizophrenia: The contribution of cognition and psychopathology. <i>Psychiatry Research</i> , 2013, 205, 192-198.	1.7	33
66	Differential diagnosis between schizophrenia and autism in adulthood: A case report. <i>Neurocase</i> , 2013, 19, 604-612.	0.2	8
67	Nonlinear analysis of electroencephalogram at rest and during cognitive tasks in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 259-266.	1.4	30
68	La psicoeducazione nella schizofrenia: evidenze di efficacia e peculiarità di intervento su pazienti e familiari. <i>Quaderni Italiani Di Psichiatria</i> , 2012, 31, 157-163.	0.1	0
69	Compulsory admissions of emergency psychiatric inpatients in Turin: The role of diagnosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 288-294.	2.5	12
70	Cognitive function and competitive employment in schizophrenia: relative contribution of insight and psychopathology. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 553-561.	1.6	24
71	Predictors of compulsory admission in schizophrenia-spectrum patients: Excitement, insight, emotion perception. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 137-145.	2.5	24
72	Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010, 45, 603-610.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Neuropsychiatric Symptoms Underlying Caregiver Stress and Insight in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 57-63.	0.7	62
74	The Complaint of Oral Malodour: Psychopathological and Personality Profiles. <i>Psychotherapy and Psychosomatics</i> , 2010, 79, 392-394.	4.0	3
75	Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 71-76.	1.7	19
76	Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. <i>Trials</i> , 2009, 10, 31.	0.7	21
77	Exploring the role of face processing in facial emotion recognition in schizophrenia. <i>Acta Neuropsychiatrica</i> , 2009, 21, 292-300.	1.0	6
78	Quality of life and psychopathology during the course of schizophrenia. <i>Comprehensive Psychiatry</i> , 2009, 50, 542-548.	1.5	21
79	Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 373-379.	2.5	35
80	Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 405-413.	2.5	49
81	Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. <i>Comprehensive Psychiatry</i> , 2008, 49, 170-176.	1.5	45
82	Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 622-629.	1.0	36
83	Neuropsychological correlates of reality distortion in schizophrenic patients. <i>Psychiatry Research</i> , 2006, 145, 49-60.	1.7	37
84	Managing the aggressive and violent patient in the psychiatric emergency. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 586-598.	2.5	40
85	Depressive and negative symptoms in schizophrenia: different effects on clinical features. <i>Comprehensive Psychiatry</i> , 2005, 46, 304-310.	1.5	65
86	Citalopram Versus Sertraline in Late-Life Nonmajor Clinically Significant Depression. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 360-369.	1.1	45
87	Relationships of Age at Onset With Clinical Features and Cognitive Functions in a Sample of Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 908-914.	1.1	44
88	Predictors of psychiatric disorders in liver transplantation candidates: Logistic regression models. <i>Liver Transplantation</i> , 2003, 9, 721-726.	1.3	38
89	A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. <i>Psychiatry Research</i> , 2002, 112, 145-152.	1.7	16
90	Donepezil in the treatment of Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 369-373.	2.5	22

#	ARTICLE	IF	CITATIONS
91	Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1155-1160.	2.5	54
92	A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. <i>Journal of Affective Disorders</i> , 2002, 70, 313-317.	2.0	45
93	Treatment of Borderline Personality Disorder With Risperidone. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 241-244.	1.1	91
94	Lymphocyte peripheral benzodiazepine receptor mRNA decreases in obsessive-compulsive disorder. <i>European Neuropsychopharmacology</i> , 2000, 10, 337-340.	0.3	8
95	Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. <i>Biological Psychiatry</i> , 1998, 43, 767-773.	0.7	54
96	AN ANALYSIS OF LYMPHOCYTE 3H-N-METHYL-SCOPOLAMINE BINDING IN NEUROLOGICAL PATIENTS. <i>Brain</i> , 1991, 114, 1759-1770.	3.7	27